share_log

Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma And Fluidda

Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma And Fluidda

Aptar扩展制药服务;宣布Aptar Pharma和Fluidda之间的独家合作
Benzinga Real-time News ·  2022/09/22 08:37
Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE:ATR) in 2019, as part of the company's strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.
亚洲网加利福尼亚州圣何塞10月23日电Aptar制药公司旗下口服吸入和鼻腔药物产品(OINDPS)合同研发服务的领先者Nanopharm今天宣布与功能呼吸成像领域的领先者Fluidda达成独家合作。两家公司将利用各自的专有技术平台,通过替代生物等效性途径,帮助加快美国食品和药物管理局(FDA)对口服吸入型仿制药(OIDP)的批准。纳米药业于2019年被Aptar(纽约证券交易所股票代码:ATR)收购,这是该公司扩大服务范围并在药物开发过程中更早与制药公司合作的战略的一部分。
This...
这...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发